Dechra Rolls Out Europe’s First Transdermal Treatment For Feline Weight Gain
Dechra Veterinary Products has launched Mirataz®, the first and only licensed transdermal mirtazapine ointment for cats in Europe and can induce significant weight gain in as little as 14 days1.
Mirataz® ointment is licensed treatment for managed body weight gain in cats suffering from poor appetite and weight loss as a result of chronic medical conditions.
The ointment, which allows for a swift response to the initial symptoms of weight loss and lack of appetite, can improve the condition and wellbeing of the patient before a definitive diagnosis has been made.
Dechra Brand Manager Claire Morgan said: “Unintended feline weight loss may be associated with serious consequences including reduced survival time. Identifying and treating weight loss early, as well as precise weight management in the longer term, can help improve feline patient’s overall health and comfort. With unintended weight loss, you can’t afford to delay treatment.”
Mirataz® enters the market as the only veterinary licensed weight gain product in Europe, with alternatives originating in the made to order veterinary specials and human medication markets.
Mirataz® is available in a 5g tube and comes in child resistant packaging. It is available now in wholesalers and more information can be found on: www.dechra.co.uk/campaigns/mirataz.
More from Dechra
- Dechra unveils Dexacortone®: a flavoured double divisible SmartTab®
- Dechra adds Otitis podcast to its online CPD library
- New Equibactin® Powder offers convenient and accurate antibiotic dosing
- New Equisolon® sachets make for convenient dosing for equine asthma
- Exploring the “good, bad and the ugly” of equine lameness diagnosis and treatment